DNA repair pathways and their therapeutic potential in lung cancer

SUMMARY:  Lung cancer is the leading cause of cancer-related mortality. According to WHO, 1.37 million deaths occur globally each year as a result of this disease. More than 70% of these cases are associated with prior tobacco consumption and/or cigarette smoking, suggesting a direct causal relationship. The development and progression of lung cancer and other malignancies involves the loss of genetic stability, resulting in acquisition of cumulative genetic changes; this affords the cell increased malignant potential. As such, an understanding of the mechanisms through which these events may occur will potentially allow for development of new anticancer therapies. This review will address the association between lung cancer and genetic instability, with a central focus on genetic mutations in the DNA damage repair pathways. In addition, we will discuss the potential clinical exploitation of these pathways, both in terms of biomarker staging, as well as through direct therapeutic targeting.

[1]  G. Pfeifer,et al.  Mutational spectra of human cancer , 2009, Human Genetics.

[2]  J. Holthuis Etoposide and teniposide , 1988, Pharmaceutisch Weekblad.

[3]  P. Hsieh,et al.  DNA mismatch repair: Molecular mechanism, cancer, and ageing , 2008, Mechanisms of Ageing and Development.

[4]  Jong Y. Park,et al.  The human 8-oxoguanine DNA N-glycosylase 1 (hOGG1) DNA repair enzyme and its association with lung cancer risk. , 2004, Pharmacogenetics.

[5]  D. Bau,et al.  Lung cancer susceptibility and genetic polymorphisms of Exo1 gene in Taiwan. , 2009, Anticancer research.

[6]  K. Osawa,et al.  MUTYH Gln324His gene polymorphism and genetic susceptibility for lung cancer in a Japanese population , 2009, Journal of experimental & clinical cancer research : CR.

[7]  D. Campa,et al.  Polymorphisms of DNA repair genes and risk of non-small cell lung cancer. , 2006, Carcinogenesis.

[8]  T. Eisen,et al.  Genetic variation in the DNA repair genes is predictive of outcome in lung cancer. , 2007, Human molecular genetics.

[9]  E. Felip,et al.  BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer. , 2004, Human molecular genetics.

[10]  J. Pascal,et al.  PARP-1 mechanism for coupling DNA damage detection to poly(ADP-ribose) synthesis. , 2013, Current opinion in structural biology.

[11]  N. Tretyakova,et al.  Tobacco smoke carcinogens, DNA damage and p53 mutations in smoking-associated cancers , 2002, Oncogene.

[12]  N. Rothman,et al.  Polymorphisms in the DNA base excision repair genes APEX1 and XRCC1 and lung cancer risk in Xuan Wei, China. , 2005, Anticancer research.

[13]  J. Luketich,et al.  Polymorphisms in DNA repair genes XPD and XRCC1 and p53 mutations in lung carcinomas of never‐smokers , 2006, Molecular carcinogenesis.

[14]  Y. Miyoshi,et al.  Decreased expression of BRCA2 mRNA predicts favorable response to docetaxel in breast cancer , 2001, International journal of cancer.

[15]  S. Carr,et al.  Mammalian Chk2 is a downstream effector of the ATM-dependent DNA damage checkpoint pathway , 1999, Oncogene.

[16]  A. D’Andrea,et al.  DNA repair pathways in clinical practice: lessons from pediatric cancer susceptibility syndromes. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  B. Hang Formation and Repair of Tobacco Carcinogen-Derived Bulky DNA Adducts , 2010, Journal of nucleic acids.

[18]  J. Bartek,et al.  The DNA-damage response in human biology and disease , 2009, Nature.

[19]  M. Lieber,et al.  The mechanism of double-strand DNA break repair by the nonhomologous DNA end-joining pathway. , 2010, Annual review of biochemistry.

[20]  J. Minna,et al.  The 630-kb lung cancer homozygous deletion region on human chromosome 3p21.3: identification and evaluation of the resident candidate tumor suppressor genes. The International Lung Cancer Chromosome 3p21.3 Tumor Suppressor Gene Consortium. , 2000, Cancer research.

[21]  Stephen H. Friend,et al.  Potential of the Synthetic Lethality Principle , 2013, Science.

[22]  J. Minna,et al.  Sequential molecular abnormalities are involved in the multistage development of squamous cell lung carcinoma , 1999, Oncogene.

[23]  A. Fornace,et al.  Deletion of XPC leads to lung tumors in mice and is associated with early events in human lung carcinogenesis. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[24]  Zhihui Feng,et al.  A dual role of BRCA1 in two distinct homologous recombination mediated repair in response to replication arrest , 2011, Nucleic acids research.

[25]  J Zhang,et al.  High-Level mRNA of Excision Repair Cross-Complementation Group 1 Gene Is Associated With Poor Outcome of Platinum-Based Doublet Chemotherapy of Advanced Nonsmall Cell Lung Cancer Patients , 2010, Cancer investigation.

[26]  A. Rossi,et al.  The potential role of new targeted therapies in the treatment of advanced non-small-cell lung cancer , 2013 .

[27]  M. Gottesman,et al.  Multidrug resistance in cancer: role of ATP–dependent transporters , 2002, Nature Reviews Cancer.

[28]  P. Ellis,et al.  ABT-888 Confers Broad In vivo Activity in Combination with Temozolomide in Diverse Tumors , 2009, Clinical Cancer Research.

[29]  Association between the OGG1 Ser326Cys and APEX1 Asp148Glu polymorphisms and lung cancer risk: a meta-analysis , 2012, Molecular Biology Reports.

[30]  E. Liu,et al.  BRCA1 and GADD45 mediated G2/M cell cycle arrest in response to antimicrotubule agents , 2001, Oncogene.

[31]  Scott H. Kaufmann,et al.  Failure of Iniparib to Inhibit Poly(ADP-Ribose) Polymerase In Vitro , 2012, Clinical Cancer Research.

[32]  J. Minna,et al.  3p21.3 tumor suppressor cluster: prospects for translational applications. , 2005, Future oncology.

[33]  E. Birney,et al.  Patterns of somatic mutation in human cancer genomes , 2007, Nature.

[34]  Wei Wu,et al.  Association between polymorphisms in XRCC1 gene and clinical outcomes of patients with lung cancer: a meta-analysis , 2012, BMC Cancer.

[35]  S. Johnson,et al.  Increased nucleotide excision repair in cisplatin-resistant ovarian cancer cells: role of ERCC1-XPF. , 2000, Biochemical pharmacology.

[36]  D. Spigel PARP inhibitors in lung cancer. , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[37]  J. Minna,et al.  p53: a frequent target for genetic abnormalities in lung cancer. , 1989, Science.

[38]  Zhefu Ma,et al.  MDC1 interacts with Rad51 and facilitates homologous recombination , 2005, Nature Structural &Molecular Biology.

[39]  Renato Martins,et al.  Non-small cell lung cancer, version 2.2013: Featured updates to the NCCN guidelines , 2013 .

[40]  Krishna R. Kalari,et al.  Genetic association with overall survival of taxane-treated lung cancer patients - a genome-wide association study in human lymphoblastoid cell lines followed by a clinical association study , 2012, BMC Cancer.

[41]  I. Demuth,et al.  Expression pattern of the Nijmegen breakage syndrome gene, Nbs1, during murine development. , 2000, Human molecular genetics.

[42]  T. Hamilton,et al.  Platinum Resistance: The Role of DNA Repair Pathways , 2008, Clinical Cancer Research.

[43]  P. Musiani,et al.  Role of MUTYH and MSH2 in the control of oxidative DNA damage, genetic instability, and tumorigenesis. , 2009, Cancer research.

[44]  J. McLaughlin,et al.  Meta-analyses of p53 tumor suppressor gene alterations and clinicopathological features in resected lung cancers. , 1999, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[45]  T. Halazonetis,et al.  Genomic instability — an evolving hallmark of cancer , 2010, Nature Reviews Molecular Cell Biology.

[46]  L. Le Marchand,et al.  Association of the hOGG1 Ser326Cys polymorphism with lung cancer risk. , 2002, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[47]  Hong Wei,et al.  Expression of the Mismatch Repair Gene hMLH1 Is Enhanced in Non-Small Cell Lung Cancer with EGFR Mutations , 2013, PloS one.

[48]  U. Vogel,et al.  No Association Between Base Excision Repair Gene Polymorphisms and Risk of Lung Cancer , 2004, Biochemical Genetics.

[49]  Mark Yoffe,et al.  Iniparib plus chemotherapy in metastatic triple-negative breast cancer. , 2011, The New England journal of medicine.

[50]  D. Mavroudis,et al.  ERCC1 and BRAC1 mRNA Expression Levels in the Primary Tumor Could Predict the Effectiveness of the Second-Line Cisplatin-Based Chemotherapy in Pretreated Patients with Metastatic Non-small Cell Lung Cancer , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[51]  A. Rossi,et al.  Treatment of patients with small-cell lung cancer: from meta-analyses to clinical practice. , 2013, Cancer treatment reviews.

[52]  Jun Yokota,et al.  Molecular processes of chromosome 9p21 deletions in human cancers , 2003, Oncogene.

[53]  K. Dahm Functions and regulation of human artemis in double strand break repair , 2007, Journal of cellular biochemistry.

[54]  Michael M. Murphy,et al.  ATM Phosphorylates Histone H2AX in Response to DNA Double-strand Breaks* , 2001, The Journal of Biological Chemistry.

[55]  Christian Ruiz,et al.  Advancing a clinically relevant perspective of the clonal nature of cancer , 2011, Proceedings of the National Academy of Sciences.

[56]  D. Matei,et al.  Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. , 2012, The New England journal of medicine.

[57]  H. Wang,et al.  Significant association of DNA repair gene Ku80 genotypes with breast cancer susceptibility in Taiwan. , 2009, Anticancer research.

[58]  L. Dai,et al.  XRCC1 gene polymorphisms and lung cancer susceptibility: a meta-analysis of 44 case–control studies , 2012, Molecular Biology Reports.

[59]  Yun-Chul Hong,et al.  Genetic polymorphisms of ataxia telangiectasia mutated affect lung cancer risk. , 2006, Human molecular genetics.

[60]  G. Garinis,et al.  Nucleotide excision repair: new tricks with old bricks. , 2012, Trends in genetics : TIG.

[61]  M. Spitz,et al.  ATM sequence variants associate with susceptibility to non‐small cell lung cancer , 2007, International journal of cancer.

[62]  Wei Chen,et al.  Multi‐loci analysis reveals the importance of genetic variations in sensitivity of platinum‐based chemotherapy in non‐small‐cell lung cancer , 2013, Molecular carcinogenesis.

[63]  N. Bowden Nucleotide excision repair: why is it not used to predict response to platinum-based chemotherapy? , 2014, Cancer letters.

[64]  Stephen S Hecht,et al.  Lung carcinogenesis by tobacco smoke , 2012, International journal of cancer.

[65]  Takako Noguchi,et al.  Tip60 Is Regulated by Circadian Transcription Factor Clock and Is Involved in Cisplatin Resistance* , 2008, Journal of Biological Chemistry.

[66]  APE1 Asp148Glu gene polymorphism and bladder cancer risk: a meta-analysis , 2011, Molecular Biology Reports.

[67]  K. O'Byrne,et al.  Oxidative stress induced lung cancer and COPD: opportunities for epigenetic therapy , 2009, Journal of cellular and molecular medicine.

[68]  Shunichi Takeda,et al.  Single-stranded DNA-binding protein hSSB1 is critical for genomic stability , 2008, Nature.

[69]  M. Lieber,et al.  Roles of nonhomologous DNA end joining, V(D)J recombination, and class switch recombination in chromosomal translocations. , 2006, DNA repair.

[70]  Michael M Gottesman,et al.  Cisplatin Resistance: A Cellular Self-Defense Mechanism Resulting from Multiple Epigenetic and Genetic Changes , 2012, Pharmacological Reviews.

[71]  D. Quinlan,et al.  Accumulation of p53 protein correlates with a poor prognosis in human lung cancer. , 1992, Cancer research.

[72]  Beatriz Bellosillo,et al.  Diversity of genomic breakpoints in TFG-ALK translocations in anaplastic large cell lymphomas: identification of a new TFG-ALK(XL) chimeric gene with transforming activity. , 2002, The American journal of pathology.

[73]  Kum Kum Khanna,et al.  Recent Advances in Cancer Therapy Targeting Proteins Involved in DNA Double-Strand Break Repair , 2009, Clinical Cancer Research.

[74]  H. Aburatani,et al.  Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer , 2007, Nature.

[75]  M. Spitz,et al.  Prognostic significance of ataxia‐telangiectasia mutated, DNA‐dependent protein kinase catalytic subunit, and Ku heterodimeric regulatory complex 86‐kD subunit expression in patients with nonsmall cell lung cancer , 2008, Cancer.

[76]  A. Ashworth,et al.  The DNA damage response and cancer therapy , 2012, Nature.

[77]  Limin Wang,et al.  Ku80 is differentially expressed in human lung carcinomas and upregulated in response to irradiation in mice. , 2011, DNA and cell biology.

[78]  Robert W Sobol,et al.  Base excision repair and lesion-dependent subpathways for repair of oxidative DNA damage. , 2011, Antioxidants & redox signaling.

[79]  Roger A. Jones,et al.  Formation of diastereomeric benzo[a]pyrene diol epoxide-guanine adducts in p53 gene-derived DNA sequences. , 2004, Chemical research in toxicology.

[80]  Dong Wang,et al.  APE1 overexpression is associated with cisplatin resistance in non-small cell lung cancer and targeted inhibition of APE1 enhances the activity of cisplatin in A549 cells. , 2009, Lung cancer.

[81]  Association between the NBS1 Glu185Gln polymorphism and lung cancer risk: a systemic review and meta-analysis , 2013, Molecular Biology Reports.

[82]  M. Gallucci,et al.  Tumor specific modulation of KU70/80 DNA binding activity in breast and bladder human tumor biopsies , 2001, Oncogene.

[83]  Carlos Caldas,et al.  The implications of clonal genome evolution for cancer medicine. , 2013, The New England journal of medicine.

[84]  D. Butkiewicz,et al.  Influence of DNA repair gene polymorphisms on prognosis in inoperable non‐small cell lung cancer patients treated with radiotherapy and platinum‐based chemotherapy , 2012, International journal of cancer.

[85]  Seungbok Lee,et al.  A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing. , 2012, Genome research.

[86]  M. Weitzman,et al.  The MRN complex in double‐strand break repair and telomere maintenance , 2010, FEBS letters.

[87]  J. Bujnicki,et al.  Databases and Bioinformatics Tools for the Study of DNA Repair , 2011, Molecular biology international.

[88]  J. Kobayashi,et al.  Molecular mechanism of the recruitment of NBS1/hMRE11/hRAD50 complex to DNA double-strand breaks: NBS1 binds to gamma-H2AX through FHA/BRCT domain. , 2004, Journal of radiation research.

[89]  R. Sobti,et al.  Contrasting impact of DNA repair gene XRCC1 polymorphisms Arg399Gln and Arg194Trp on the risk of lung cancer in the north-Indian population. , 2007, DNA and cell biology.

[90]  Yunmei Ma,et al.  Hairpin Opening and Overhang Processing by an Artemis/DNA-Dependent Protein Kinase Complex in Nonhomologous End Joining and V(D)J Recombination , 2002, Cell.

[91]  H. van Steeg,et al.  Oxidative DNA damage and nucleotide excision repair. , 2013, Antioxidants & redox signaling.

[92]  M. Fiegl,et al.  Prognostic and Predictive Value of Cell Cycle Deregulation in Non-Small-Cell Lung Cancer , 2012, Pathobiology.

[93]  Li Wang,et al.  MK-4827, a PARP-1/-2 inhibitor, strongly enhances response of human lung and breast cancer xenografts to radiation , 2012, Investigational New Drugs.

[94]  Fengli Wang,et al.  The role of PARP1 in the DNA damage response and its application in tumor therapy , 2012, Frontiers of Medicine.

[95]  L. Mullenders,et al.  The role of XPC: implications in cancer and oxidative DNA damage. , 2011, Mutation research.

[96]  K. O'Byrne,et al.  Generation and Characterisation of Cisplatin-Resistant Non-Small Cell Lung Cancer Cell Lines Displaying a Stem-Like Signature , 2013, PloS one.

[97]  A. Borczuk,et al.  PARP inhibition selectively increases sensitivity to cisplatin in ERCC1-low non-small cell lung cancer cells. , 2013, Carcinogenesis.

[98]  P. Johnston,et al.  The role of BRCA1 in the cellular response to chemotherapy. , 2004, Journal of the National Cancer Institute.

[99]  Yufei Wang,et al.  Role of ERCC1 variants in response to chemotherapy and clinical outcome of advanced non-small cell lung cancer , 2014, Tumor Biology.

[100]  Brian H. Dunford-Shore,et al.  Somatic mutations affect key pathways in lung adenocarcinoma , 2008, Nature.

[101]  David J. Chen,et al.  The endless tale of non-homologous end-joining , 2008, Cell Research.

[102]  S. Ahmad Platinum–DNA Interactions and Subsequent Cellular Processes Controlling Sensitivity to Anticancer Platinum Complexes , 2010, Chemistry & biodiversity.

[103]  M. F. White,et al.  hSSB1 interacts directly with the MRN complex stimulating its recruitment to DNA double-strand breaks and its endo-nuclease activity , 2011, Nucleic acids research.

[104]  M. Evans,et al.  Poly(ADP-ribose) Polymerase 1 (PARP-1) Binds to 8-Oxoguanine-DNA Glycosylase (OGG1)* , 2011, The Journal of Biological Chemistry.

[105]  Enni Markkanen,et al.  Oxygen as a friend and enemy: How to combat the mutational potential of 8-oxo-guanine. , 2010, DNA repair.

[106]  M. Gatei,et al.  Ataxia Telangiectasia Mutated (ATM) Kinase and ATM and Rad3 Related Kinase Mediate Phosphorylation of Brca1 at Distinct and Overlapping Sites , 2001, The Journal of Biological Chemistry.

[107]  Y. Bignon,et al.  Inhibition of BRCA1 leads to increased chemoresistance to microtubule-interfering agents, an effect that involves the JNK pathway , 2001, Oncogene.

[108]  M. Lieber,et al.  The Mechanism of Human Nonhomologous DNA End Joining* , 2008, Journal of Biological Chemistry.

[109]  M. Evans,et al.  Accumulation of Oxidatively Induced DNA Damage in Human Breast Cancer Cell Lines Following Treatment with Hydrogen Peroxide , 2007, Cell cycle.

[110]  Eric F. Johnson,et al.  ABT-888, an Orally Active Poly(ADP-Ribose) Polymerase Inhibitor that Potentiates DNA-Damaging Agents in Preclinical Tumor Models , 2007, Clinical Cancer Research.

[111]  A. Fedier,et al.  The effect of loss of Brca1 on the sensitivity to anticancer agents in p53-deficient cells. , 2003, International journal of oncology.

[112]  Josef Jiricny,et al.  Mediating mismatch repair , 2000, Nature Genetics.

[113]  K. Khanna,et al.  Involvement of Exo1b in DNA damage-induced apoptosis , 2009, Nucleic acids research.

[114]  D. Smeets,et al.  Nijmegen Breakage Syndrome: a progress report. , 1994, International journal of radiation biology.

[115]  Masato Hareyama,et al.  The combination of olaparib and camptothecin for effective radiosensitization , 2012, Radiation oncology.

[116]  A. Chen,et al.  Molecular Pathways: Targeting PARP in Cancer Treatment , 2012, Clinical Cancer Research.

[117]  I. Herskowitz,et al.  Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[118]  C. Redon,et al.  Histone H2AX in DNA damage and repair. , 2003, Cancer biology & therapy.

[119]  Qi-En Wang,et al.  Stem cell protein Piwil2 modulates chromatin modifications upon cisplatin treatment. , 2011, Mutation research.

[120]  Y. T. Kim,et al.  Proteins involved in DNA damage response pathways and survival of stage I non-small-cell lung cancer patients. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[121]  P. Sung Catalysis of ATP-dependent homologous DNA pairing and strand exchange by yeast RAD51 protein. , 1994, Science.

[122]  Sudhir Srivastava,et al.  Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. , 2004, Journal of the National Cancer Institute.

[123]  Rui-Xi Hua,et al.  Associations between polymorphisms of the XPC gene and lung cancer susceptibility: a meta-analysis , 2014, Tumor Biology.

[124]  P. Cole,et al.  The DNA-Binding Domain of Human PARP-1 Interacts with DNA Single-Strand Breaks as a Monomer through Its Second Zinc Finger , 2011, Journal of molecular biology.

[125]  C. Wang,et al.  Association of BRCA1 with the hRad50-hMre11-p95 complex and the DNA damage response. , 1999, Science.

[126]  J. Nickoloff,et al.  Regulation of DNA double-strand break repair pathway choice , 2008, Cell Research.

[127]  F. Dick,et al.  Chromosome instability and deregulated proliferation: an unavoidable duo , 2012, Cellular and Molecular Life Sciences.

[128]  Steven J. M. Jones,et al.  Comprehensive genomic characterization of squamous cell lung cancers , 2012, Nature.

[129]  K. Khanna,et al.  DNA double-strand breaks: signaling, repair and the cancer connection , 2001, Nature Genetics.

[130]  Linking environmental carcinogen exposure to TP53 mutations in human tumours using the human TP53 knock‐in (Hupki) mouse model , 2010 .

[131]  H. Hsu,et al.  Lung cancer susceptibility and prognosis associated with polymorphisms in the nonhomologous end‐joining pathway genes , 2009, Cancer.

[132]  T. O'Connor,et al.  Enhancement of Synthetic Lethality via Combinations of ABT-888, a PARP Inhibitor, and Carboplatin In Vitro and In Vivo Using BRCA1 and BRCA2 Isogenic Models , 2012, Molecular Cancer Therapeutics.

[133]  David J. Chen,et al.  hSSB1 rapidly binds at the sites of DNA double-strand breaks and is required for the efficient recruitment of the MRN complex , 2010, Nucleic acids research.

[134]  R. Kanaar,et al.  Dealing with DNA damage: relationships between checkpoint and repair pathways. , 2010, Mutation research.

[135]  Michael Thomas,et al.  Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. , 2013, The New England journal of medicine.

[136]  F. Guengerich,et al.  Common and uncommon cytochrome P450 reactions related to metabolism and chemical toxicity. , 2001, Chemical research in toxicology.

[137]  V. O'shea,et al.  Base-excision repair of oxidative DNA damage , 2007, Nature.

[138]  F. Lin,et al.  ATM-Mediated Stabilization of hMutL DNA Mismatch Repair Proteins Augments p53 Activation during DNA Damage , 2004, Molecular and Cellular Biology.

[139]  C. Collins,et al.  In Brief: Chromothripsis and cancer , 2013, Journal of Pathology.

[140]  Li Ding,et al.  Genomic Landscape of Non-Small Cell Lung Cancer in Smokers and Never-Smokers , 2012, Cell.

[141]  Xiaoye Zhang,et al.  Association between the hOGG1 Ser326Cys polymorphism and lung cancer susceptibility: a meta-analysis based on 22,475 subjects , 2013, Diagnostic Pathology.

[142]  P. Hainaut,et al.  30 years and a long way into p53 research. , 2009, The Lancet. Oncology.

[143]  K. O'Byrne,et al.  Human single-stranded DNA binding proteins are essential for maintaining genomic stability , 2013, BMC Molecular Biology.

[144]  E. Parlanti,et al.  8-Oxoguanine DNA damage: at the crossroad of alternative repair pathways. , 2003, Mutation research.